ReviewCells2021
Pitfalls and Caveats in Applying Chromogenic Immunostaining to Histopathological Diagnosis.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 30 citations in OpenAlex.
- Biomimetic Vascular Scaffold with Seamless Electrospun Aligned Nanofiber Conduit and 3D-Printed Coil Reinforcement.Advanced healthcare materials · 2026Article
- Sodium-glucose transporters SGLT1 and SGLT2 in equine renal, hepatic and pancreatic tissue.BMC veterinary research · 2025Article
- Immunophenotypic Panel for Comprehensive Characterization of Aggressive Thyroid Carcinomas.Cells · 2025Article
- Visualizing the Cellular and Subcellular Distribution of Fms-like Tyrosine Kinase 3 (Flt3) and Other Neuronal Proteins Using Alkaline Phosphatase (AP) Immunolabeling.International journal of molecular sciences · 2025Article
- Diagnostic Dilemma in Intra-abdominal Cancers.JNMA; journal of the Nepal Medical Association · 2025Article
- Improving quality control of whole slide images by explicit artifact augmentation.Scientific reports · 2024Article
- Enzyme-labeled liquid-based cytology (ELLBC): a new noninvasive diagnostic method for bladder cancers.Journal of cancer research and clinical oncology · 2024Article
- Article
- Evaluation of Selected Markers in Kidneys of Cynomolgus Monkey (Comparative medicine · 2023Article
- Blocking Nonspecific Interactions Using Y-Shape Poly(ethylene glycol).International journal of molecular sciences · 2023Article
- Beyond conventional microscopy: Observing kidney tissues by means of fourier ptychography.Frontiers in physiology · 2023Article
- Companion diagnostic requirements for spatial biology using multiplex immunofluorescence and multispectral imaging.Frontiers in molecular biosciences · 2023Review
- Immunohistochemical Detection of Estrogen Receptor-Beta (ERβ) with PPZ0506 Antibody in Murine Tissue: From Pitfalls to Optimization.Biomedicines · 2022Article
- Enzyme-labeled Antigen Method: Factors Influencing the Deterioration of Antigen-binding Activity of Specific Antibodies during Formalin Fixation and Paraffin Embedding.Acta histochemica et cytochemica · 2022Article
- Clinical Significance of TET2 in Female Cancers.Frontiers in bioengineering and biotechnology · 2022Article
- Article
- Tissue Multiplex Analyte Detection in Anatomic Pathology - Pathways to Clinical Implementation.Frontiers in molecular biosciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromogenic immunohistochemistry (immunostaining using an enzyme-labeled probe) is an essential histochemical technique for analyzing pathogenesis and making a histopathological diagnosis in routine pathology services. In neoplastic lesions, immunohistochemistry allows the study of specific clinical and biological features such as histogenesis, behavioral characteristics, therapeutic targets, and prognostic biomarkers. The needs for appropriate and reproducible methods of immunostaining are prompted by technical development and refinement, commercial availability of a variety of antibodies, advanced applicability of immunohistochemical markers, accelerated analysis of clinicopathological correlations, progress in molecular targeted therapy, and the expectation of advanced histopathological diagnosis. However, immunostaining does have various pitfalls and caveats. Pathologists should learn from previous mistakes and failures and from results indicating false positivity and false negativity. The present review article describes various devices, technical hints, and trouble-shooting guides to keep in mind when performing immunostaining.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.